Patients with newly diagnosed T2DM were randomized (visit 1) to receive POLYCHEM or SDC for 16 weeks, after which, if there was regression of diabetic hyperglycemia (visit 2), drug therapy was suspended
That could go up easily to 5,000 or even 10,000 IU per day, depending on their health status
GLP-1 receptor agonists enhance glucose-dependent insulin secretion and promote satiety, whilst SGLT2 inhibitors block renal glucose reabsorption causing urinary glucose excretion
Patients were calling up to request appointments to be given (Mounjaro), which then took up a lot of our admin time and time away from other unwell patients. Another GP said they were concerned about patients needing to switch from buying the drug privately and asking for it on the NHS
This innovative study is going to be invaluable in exploring how best to address these facial alterations, with results so far being very promising. MICHAEL SOMENEK, MD CLINICAL TRIAL INVESTIGATOR WASHINGTON DC, UNITED STATES Galdermas broad portfolio addresses key patient and healthcare professional needs Galderma is well-positioned to address these alterations, given its expertise and experience in dermatology, specialized range of injectable treatments and skincare products, and its patient-centric approach, developed in close collaboration with leading healthcare professionals
